patients with a diagnosis of AIH who required the addition of tacrolimus as a third line agent.

**Methods**  
The tacrolimus database for the Regional Liver Unit, Royal Victoria Hospital was reviewed to identify all patients with AIH who had been treated with tacrolimus from Jan 2010 until August 2017. Records were cross referenced with the diagnostic coding department. Demographic details, indications for tacrolimus therapy, clinical and biochemical outcomes were recorded.

**Results**  
30 patients were identified (24 (80%) female, mean age 40.7 years, range 19–81 years). 27 of the 30 patients were initially treated with azathioprine of whom 21 (78%) discontinued treatment due to adverse effects including blood dyscrasias and 6 (22%) were switched to tacrolimus due to treatment failure. Three of 30 patients were started on tacrolimus instead of azathioprine or mycophenolate. Two of these patients had previous episodes of pancytopenia at the time of commencing treatment for AIH and azathioprine/mycopheno- late were excluded as a treatment option. One of the patients was commenced on prednisolone and tacrolimus without another steroid sparing agent trailed for other reasons. 26 (87%) of 30 patients remain on tacrolimus, of whom 11 (42%) had normalisation of transaminases and a further 12 (46%) had improvement of transaminases. Liver function tests in the 3 (11.5%) remaining patients were deranged but static. Of note all three had established cirrhosis at the time of AIH diagnosis. Of the four whose tacrolimus therapy was discontinued, two stopped due to side effects, 1 is deceased (not tacrolimus related) and one stopped due to commencing infliximab for IBD.

**Conclusions**  
Tacrolimus is a safe and well tolerated treatment for AIH when first line therapy has failed. In the cohort observed, only 6% failed to tolerate tacrolimus and biochemical parameters were improved or normalised in 88% of patients who remained on tacrolimus therapy.

---

**Abstracts**

**PTH-085**  
**USING ELF TESTS IN PRIMARY AND SECONDARY CARE TO IDENTIFY PATIENTS WITH ADVANCE FIBROSIS**

Charlotte Cook*, Alison Burnidge, Janisha Patel, University Hospital Southampton, Southampton, UK

10.1136/gutjnl-2018-BSGAbstracts.241

**Introduction**  
In 2016 NICE NAFLD guidelines recommended Enhance Liver Fibrosis (ELF) as a validated test to assess advanced liver fibrosis.

This study aims

ELF tests were performed, 166 from by GP practices and 175 by UHS hepatology service. 89 were from other organisations to assess the relationship with standard investigations used in a hepatology clinic for NAFLD patients (including transient elastography) and the newly commissioned ELF test in a real world setting.

**Methods**  
The study looked at all new patients diagnosed with NAFLD via the hepatology outpatient clinic at University Hospital Southampton between November 2016 and May 2017.

Each patient had their demographics (age, gender, weight) and comorbidities (diabetes, hypertension, dyslipidaemia) assessed. Transient elastography, USS and ELF Result (when performed) were reviewed.

The ELF was categorised as no/mild fibrosis if <7.5, moderate fibrosis if ≥7.5 and<10.5, advanced fibrosis if ≥10.5.

The ELF tests requested over the same period were analysed review the source of the request.

**Results**  
175 people were diagnosed with NAFLD through hepatology clinic. All patients had transient elastography performed. The mean LSM Result was 14.6 (range 3.3–75), with a mean CAP score of 313.6 (range 100–400). Of 175 new diagnoses, 101 patients were male (mean weight 99 kg, median age 52 years) and 74 were female (87.1 kg and 57 years).

69 patients had type 2 diabetes mellitus, 74 had hypertension and 66 had dyslipidaemia. 30 patients had all 3 (16 were female with a mean weight 96.5 kg and mean LSM 18.5 kPa and 14 were male, 100.7 kg and 19.3 kPa).

With transient elastography, 59 patients had LSM <6 kPa, 68 were 6.1–12 kPa, 23 were 12.1–20 kPa and 25>20.1 kPa. This suggested 48 (27%) patients had advanced fibrosis or cirrhosis. The remaining 127 (73%) patients did not require hepatology review.

**Conclusions**  
This study looked at the cohort of new diagnoses of NAFLD in a teaching hospital using standard tests and ELF score. Currently, access to transient elastography is secondary care based. The preliminary data in this study shows that the ELF test is a good first line investigation for GPs suspecting NAFLD in a patient with type 2 diabetes and obesity or incidental finding of fatty liver. It promotes the need to look beyond the routine liver panel test and identify the aetiology of liver disease and assess extent of liver fibrosis; in turn, to generate appropriate secondary care referrals and incorporate efficiency. Further assessment of the use of ELF in this setting continues.

---

**PTH-086**  
**VIRTUAL HEPATITIS B CLINICS SIGNIFICANTLY IMPROVE COST AND CLINICAL EFFECTIVENESS**

Douglas Corrigal*, Sarah Fairclough, Linda Porter, Katrina White, Denise Killworth, Gavin Wright, Basildon and Thurrock University Hospital, Basildon, UK

10.1136/gutjnl-2018-BSGAbstracts.242

**Introduction**  
Chronic Hepatitis B (HBV) infection requires regular hepatology review to assess for potential flares, need for therapy and/or progression to advanced liver disease and its complications. The majority of patients are chronic carriers who feel perfectly well and can find repeated clinic visits difficult, unnecessary and impinge on other commitments (e.g. employment, social and child care). As a Result there is a high rate of missed appointments and or patients lost to follow up, with the potential for missed viral flares. A nurse-led virtual clinic allows remote monitoring of these patients as recommended by national and international guidelines.1 2

**Methods**  
Patients with stable chronic HBV suitable for telephone clinic follow-up were identified. The criteria used were: not on/received HBV therapy, no significant comorbidities or risk factors for liver disease, low viral load (<2000 in/ml), F0/1 disease, low and stable alpha-fetoprotein (AFP), unremarkable imaging, and no transaminitis/native liver derangement.

Over a 2.5 year period from 01.02.2014, patients meeting the criteria were offered 6-monthly virtual clinic review. Patients had surveillance blood test within 4 weeks of their